Thanks all for the input. My concern was mainly around the product itself. Yes execution risk is a factor. But at the end of the day unless you have a product that meets endpoints then it doesn’t matter who makes the decisions. If the product works then even I could make the company share price grow exponentially.
would it be a fair assumption to make that product efficacy is not a worry for PAR shareholders.
Thanks all for the input. My concern was mainly around the...
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 25.0¢ | 23.0¢ | $101.6K | 424.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 144266 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 18540 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |